Stepan Co
Chemicals
Stepan Co (SCL) Stock News
The latest SCL headlines and market coverage — 6 recent stories, updated throughout the day.
- GlobeNewswire Inc.·
New Drug Application Submission Initiated for Zipalertinib Plus Chemotherapy in First-Line EGFR Exon 20 Insertion Mutation NSCLC for Review Under FDA Real-Time Oncology Review Program
Cullinan Therapeutics announced the initiation of a New Drug Application (NDA) submission to the FDA for zipalertinib in combination with platinum-based chemotherapy for treating previously untreated EGFR exon 20 insertion NSCLC. The Phase 3 REZILIENT3 trial met its primary endpoint, demonstrating statistically significant improvement in median progression-free survival. The NDA submission is expected to be completed by year-end 2026 under the FDA's Real-Time Oncology Review program.
- Zacks Investment Research·
GSK Presents Jideytro Data for Potential Use in First-Line NSCLC
GSK announced positive data from the ARROS-1 study showing Jideytro (zidesamtinib) achieved a 94% response rate in first-line ROS1-positive NSCLC patients, with 90% remaining progression-free at 12 months and 70% of patients with brain metastases achieving complete tumor clearance. The drug was acquired through GSK's purchase of Nuvalent and is expected to support a supplemental FDA application for first-line use expansion.
- Zacks Investment Research·
AZN's Tagrisso Plus Orpathys Study in First-Line NSCLC Meets Goal
AstraZeneca announced positive Phase III SANOVO study results showing that Tagrisso (osimertinib) combined with Orpathys (savolitinib) significantly improved progression-free survival versus Tagrisso monotherapy in treatment-naïve patients with EGFR-mutated advanced NSCLC with MET overexpression. The combination also demonstrated encouraging overall survival improvements. These results could expand the clinical utility of the combination to first-line treatment settings.
- GlobeNewswire Inc.·Neutral
DISCLOSURE OF THE NUMBER OF SHARES FORMING THE CAPITAL AND OF THE TOTAL NUMBER OF VOTING RIGHTS AS OF 31 JULY 2026
VINCI, a French public limited company, disclosed its capital structure as of 31 July 2026, with 587,033,654 total shares and €1,467,584,135.00 in share capital. The company announced the implementation of its share buyback programme through a share purchase agreement signed with an investment partner.
- Benzinga·
Scilex (SCLX) Stock Jumps After Dream Bowl Meme Coin Listing Update: Why Is It Moving?
Scilex Holding Company shares surged 18.79% after announcing that its Dream Bowl I Meme Coin tokens will begin trading on Biconomy Exchange as early as June 23. The listing is expected to improve liquidity and enable broader distribution for eligible token holders. Scilex is a biotech company focused on non-opioid pain management products.
- GlobeNewswire Inc.·
Stoneport Advisors Commodity Long Short ETF (SCLS) to Close
Tidal Financial Group and Stoneport Advisors announced the planned closure and liquidation of the Stoneport Advisors Commodity Long Short ETF (SCLS). The fund will be delisted from Nasdaq on June 16, 2026, with liquidation completed by June 18, 2026. Shareholders can sell their shares in the secondary market before the closing date.